Daily Newsletter

13 October 2023

Daily Newsletter

13 October 2023

WHO announces €1.1bn collaboration to eradicate polio

The investment will ensure that 370 million children in low-income countries will be vaccinated against polio each year.

Jenna Philpott October 12 2023

The European Commission, the European Investment Bank and the Bill and Melinda Gates Foundation have announced a €1.1bn ($1.17bn) financing collaboration to tackle polio and make healthcare systems more accessible in low-income countries.

The funding partnership is expected to include €500m ($531m) for the Global Polio Eradication Initiative (GPEI), including World Health Organization (WHO) and UNICEF, €500m ($531m) in investments and grants to strengthen health systems and €80m ($85m) grants for technical assistance.

Polio is a serious viral infection that mainly affects children in low-income countries. The virus attacks the nervous system, leading to paralysis and sometimes death. According to WHO, wild poliovirus cases have decreased by over 99% since 1988. However, wild poliovirus remains an endemic in Pakistan and Afghanistan, with most of the cases being found in just four subnational regions.

President of the European Commission Ursula von der Leyen said: “With 1 billion euros supported by our European investment strategy Global Gateway, we will invest in stronger health systems globally and local vaccine and medicines production, manufacturing, and administration, where it is most needed. Global cooperation has helped us put an end to the Covid-19 pandemic. Now it will help us get rid of polio once and for all.”

The GPEI was launched in 1988, as a collaborative effort between the WHO, Rotary International, the US Centers for Disease Control and Prevention, UNICEF and the Bill and Melinda Gates Foundation.

Last year, at the World Health Summit in Berlin, global leaders pledged $2.6bn in funding towards the GPEI’s 2022-2026 strategy to end polio. Seventeen countries and organisations pledged contributions, with the Bill and Melinda Gates Foundation pledging $1.2bn.

Significant opportunities and risks for disease-modifying therapies (DMTs) entering the PD market

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close